PAPER Xu X, Kwon J, Yan R, Apio C, Song S, Heo G, Yang Q, Timsina J, Liu M, Budde J, Blennow K, Zetterberg H, Lleó A, Ruiz A, Molinuevo JL, Lee VM, Deming Y, Heslegrave AJ, Hohman TJ, Pastor P, Peskind ER, Albert MS, Morris JC, Park T, Cruchaga C, Sung YJ
JAMA Netw Open. 2025 Mar 3;8(3):e250562. PubMed.
Rush University Medical CenterUnited States
Children's Hospital of Philadelphia
THERAPEUTICS 1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione AbbVie Cerevel Therapeutics, LLC. Pfizer PF-06649751 CVL-751 Small Molecule Other Neurotransmitters From 2014 to 2016, Pfizer conduced Phase 1 trials of single- and
University of Eastern FinlandFinland
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, GermanyGermany
PAPER Ti Y, Liu F, Ma Y, Zhu Q, Xie C, Xia H, Chen J
Clin Lab. 2025 Mar 1;71(3) PubMed.
PAPER Guo JL, Huang TY, Zhang Z, Niu K, Gongbikai X, Gong XL, Wang XM, Zhang T
Sheng Li Xue Bao. 2025 Feb 25;77(1):13-24. PubMed.
PAPER Zarnowska A, Milewska M, Rokicka G, Kacprzyk K, Panczyk M, Folwarski M, Szostak-Węgierek D
Nutr Hosp. 2025 Mar 6; Epub 2025 Mar 6 PubMed.
PAPER Li T, Chen J, Xie Z, Fang J, Wu Q, Cao X, Chen Z, Wang Y, Fan Q, Wang Q, Liu J
Front Pharmacol. 2025;16:1528590. Epub 2025 Feb 24 PubMed.